Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT05297448 | Evaluation of Rifaximin SSD for Delaying Encephalopathy Decompensation in Patients With Cirrhosis | PHASE3 | ACTIVE NOT_RECRUITING | 466 | — | — | Aug 3, 2022 | Jan 1, 2026 | Sep 10, 2025 | 188 | United States, Australia +15 |
| NCT05071716 | Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis | PHASE3 | ACTIVE NOT_RECRUITING | 524 | — | — | Apr 7, 2022 | Sep 1, 2025 | Jul 24, 2025 | 150 | United States, Australia +2 |
| Arm | Type | Description |
|---|---|---|
| Rifaximin SSD-40mg IR | EXPERIMENTAL | - |
| Placebo | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| Rifaximin SSD | DRUG | Rifaximin Solid Soluble Dispersion Immediate Release Twice Daily |
| Placebo | DRUG | Placebo Twice Daily |
Key Inclusion Criteria: * Diagnosis of liver cirrhosis with medically controlled ascites (\>30 days) not requiring therapeutic paracentesis (could have had paracentesis in the past). * Conn (West Haven Criteria) score of \< 2. * Mini-Mental State Examination (MMSE) score \> 24 at screening. * ≥ 18 ...